Daptomycin + Vancomycin
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complicated Skin or Skin Structure Infection
Conditions
Complicated Skin or Skin Structure Infection
Trial Timeline
Jul 15, 2010 → Nov 17, 2011
NCT ID
NCT01175707About Daptomycin + Vancomycin
Daptomycin + Vancomycin is a approved stage product being developed by Merck for Complicated Skin or Skin Structure Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT01175707. Target conditions include Complicated Skin or Skin Structure Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01419184 | Approved | Completed |
| NCT01196169 | Approved | Terminated |
| NCT01175707 | Approved | Terminated |
| NCT00695903 | Phase 2 | Terminated |
| NCT00426933 | Phase 2 | Completed |
| NCT00295178 | Approved | Completed |
Competing Products
20 competing products in Complicated Skin or Skin Structure Infection